SaphoBio (tweet dated 2026-08-02) will present at the Peptides for Women event in San Francisco the following week, highlighting growing momentum in women's health and peptide therapeutics. The company is promoting lot-release testing capabilities—USP <1223> rapid sterility and USP <85> endotoxins—and outreach to compounding pharmacies and clinicians for personalized treatment workflows.
SaphoBio announced on 2026-08-02 they will attend and present at the Peptides for Women event in San Francisco "next week."
We're excited to attend and present at Peptides for Women event in San Francisco next week!
Two waves - women's health and peptide revolution are gaining real momentum.
For our part - we're focused on lot release testing (including USP <1223> rapid sterility and USP <85> endotoxins testing) and partnering with compounding pharmacies who, together with clinicians are working on personalized approaches to health.
Are you attending? Registration link in comment below!
@jefftangx